| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Access to essential medicines for children with cancer: a joint SIOP-CCI position statement
|
Denburg, Avram
|
|
2017
|
18 |
1 |
p. 20-22
|
artikel
|
| 2 |
A common global risk stratification system for hepatoblastoma
|
Shaikh, Furqan
|
|
2017
|
18 |
1 |
p. 13-15
|
artikel
|
| 3 |
An unclichéd cancer
|
Murdy, Abigail Grace
|
|
2017
|
18 |
1 |
p. 27
|
artikel
|
| 4 |
Assisted dying legislation in Victoria, Australia
|
Kenyon, Georgina
|
|
2017
|
18 |
1 |
p. e8
|
artikel
|
| 5 |
Biosimilar and generic cancer drugs unlikely to bend cost curve in the USA
|
Bennett, Charles L
|
|
2017
|
18 |
1 |
p. 22-23
|
artikel
|
| 6 |
Cabozantinib improves clinical outcomes in renal cancer
|
Das, Manjulika
|
|
2017
|
18 |
1 |
p. e2
|
artikel
|
| 7 |
Cancer control reform in Nigeria
|
Fatokun, Omotayo
|
|
2017
|
18 |
1 |
p. 19-20
|
artikel
|
| 8 |
Cancer is no joke
|
Morgan, Jules
|
|
2017
|
18 |
1 |
p. 27
|
artikel
|
| 9 |
Can modelling of PSA dynamics accelerate drug development for prostate cancer?
|
Tannock, Ian F
|
|
2017
|
18 |
1 |
p. 16-18
|
artikel
|
| 10 |
Cannabis: high time for evidence-based policies
|
The Lancet Oncology,
|
|
2017
|
18 |
1 |
p. 1
|
artikel
|
| 11 |
Challenges of data sharing: valuable but costly?
|
Davis, Ian D
|
|
2017
|
18 |
1 |
p. 15-16
|
artikel
|
| 12 |
Clonal haemopoiesis and therapy-related myeloid malignancies in elderly patients: a proof-of-concept, case-control study
|
Gillis, Nancy K
|
|
2017
|
18 |
1 |
p. 112-121
|
artikel
|
| 13 |
Defining cancer survivors, their needs, and perspectives on survivorship health care in the USA
|
Mayer, Deborah K
|
|
2017
|
18 |
1 |
p. e11-e18
|
artikel
|
| 14 |
Duloxetine lessens joint pain in early-stage breast cancer
|
Tanday, Sanjay
|
|
2017
|
18 |
1 |
p. e10
|
artikel
|
| 15 |
Effects of sodium thiosulfate versus observation on development of cisplatin-induced hearing loss in children with cancer (ACCL0431): a multicentre, randomised, controlled, open-label, phase 3 trial
|
Freyer, David R
|
|
2017
|
18 |
1 |
p. 63-74
|
artikel
|
| 16 |
Estimation of tumour regression and growth rates during treatment in patients with advanced prostate cancer: a retrospective analysis
|
Wilkerson, Julia
|
|
2017
|
18 |
1 |
p. 143-154
|
artikel
|
| 17 |
Evaluation of effectiveness of survivorship programmes: how to measure success?
|
Halpern, Michael T
|
|
2017
|
18 |
1 |
p. e51-e59
|
artikel
|
| 18 |
Follow-up care of cancer survivors: challenges and solutions
|
Jacobs, Linda A
|
|
2017
|
18 |
1 |
p. e19-e29
|
artikel
|
| 19 |
Integrating primary care providers in the care of cancer survivors: gaps in evidence and future opportunities
|
Nekhlyudov, Larissa
|
|
2017
|
18 |
1 |
p. e30-e38
|
artikel
|
| 20 |
Live better with Cancer
|
Hook, Kayleigh
|
|
2017
|
18 |
1 |
p. 28
|
artikel
|
| 21 |
Looking back, moving forward: the evolution of cancer survivorship care
|
Rosenberg, Shoshana M
|
|
2017
|
18 |
1 |
p. 18-19
|
artikel
|
| 22 |
Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study
|
Hellmann, Matthew D
|
|
2017
|
18 |
1 |
p. 31-41
|
artikel
|
| 23 |
One week and a day
|
Denny, Victoria
|
|
2017
|
18 |
1 |
p. 29
|
artikel
|
| 24 |
Osimertinib effective in EGFR T790M-positive lung cancer
|
Mayor, Susan
|
|
2017
|
18 |
1 |
p. e9
|
artikel
|
| 25 |
Palbociclib improves survival in advanced breast cancer
|
Burki, Talha Khan
|
|
2017
|
18 |
1 |
p. e1
|
artikel
|
| 26 |
Personalised vaccine against acute myeloid leukaemia
|
Burki, Talha Khan
|
|
2017
|
18 |
1 |
p. e7
|
artikel
|
| 27 |
Polycythaemia vera and precision medicine: a prescription for the 21st century
|
Spivak, Jerry L
|
|
2017
|
18 |
1 |
p. 9-11
|
artikel
|
| 28 |
Predicting therapy-related myeloid neoplasms—and preventing them?
|
Steensma, David P
|
|
2017
|
18 |
1 |
p. 11-13
|
artikel
|
| 29 |
Prediction of overall survival for patients with metastatic castration-resistant prostate cancer: development of a prognostic model through a crowdsourced challenge with open clinical trial data
|
Guinney, Justin
|
|
2017
|
18 |
1 |
p. 132-142
|
artikel
|
| 30 |
Preleukaemic clonal haemopoiesis and risk of therapy-related myeloid neoplasms: a case-control study
|
Takahashi, Koichi
|
|
2017
|
18 |
1 |
p. 100-111
|
artikel
|
| 31 |
Progress in PARP inhibitors beyond BRCA mutant recurrent ovarian cancer?
|
González Martín, Antonio
|
|
2017
|
18 |
1 |
p. 8-9
|
artikel
|
| 32 |
Provision of integrated psychosocial services for cancer survivors post-treatment
|
Recklitis, Christopher J
|
|
2017
|
18 |
1 |
p. e39-e50
|
artikel
|
| 33 |
Raising the bar on first-line immunotherapy in lung cancer
|
Lin, Jessica J
|
|
2017
|
18 |
1 |
p. 2-3
|
artikel
|
| 34 |
Reducing cisplatin ototoxicity in children: some hope and many questions
|
Bouffet, Eric
|
|
2017
|
18 |
1 |
p. 6-7
|
artikel
|
| 35 |
Resilient Women
|
Lobo, Patricia
|
|
2017
|
18 |
1 |
p. 30
|
artikel
|
| 36 |
Risk-stratified staging in paediatric hepatoblastoma: a unified analysis from the Children's Hepatic tumors International Collaboration
|
Meyers, Rebecka L
|
|
2017
|
18 |
1 |
p. 122-131
|
artikel
|
| 37 |
Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study
|
Rudin, Charles M
|
|
2017
|
18 |
1 |
p. 42-51
|
artikel
|
| 38 |
Rovalpituzumab tesirine and DLL3: a new challenge for small-cell lung cancer
|
Rossi, Antonio
|
|
2017
|
18 |
1 |
p. 3-5
|
artikel
|
| 39 |
Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial
|
Swisher, Elizabeth M
|
|
2017
|
18 |
1 |
p. 75-87
|
artikel
|
| 40 |
Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study
|
Passamonti, Francesco
|
|
2017
|
18 |
1 |
p. 88-99
|
artikel
|
| 41 |
Small benefits in trastuzumab-related cardiotoxicity
|
Das, Manjulika
|
|
2017
|
18 |
1 |
p. e5
|
artikel
|
| 42 |
58th American Society of Hematology Annual Meeting
|
Smith, Lan-Lan
|
|
2017
|
18 |
1 |
p. 26
|
artikel
|
| 43 |
The Cells of Baldwin County
|
Mariotti, Laura
|
|
2017
|
18 |
1 |
p. 28-29
|
artikel
|
| 44 |
17th World Conference on Lung Cancer
|
Collingridge, David
|
|
2017
|
18 |
1 |
p. 25
|
artikel
|
| 45 |
TILs in metastatic breast cancer—no surprises, but more questions
|
Chan, Arlene
|
|
2017
|
18 |
1 |
p. 5-6
|
artikel
|
| 46 |
Trastuzumab biosimilar shows potential for breast cancer
|
Baker, Holly
|
|
2017
|
18 |
1 |
p. e4
|
artikel
|
| 47 |
Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective analysis of the CLEOPATRA study
|
Luen, Stephen J
|
|
2017
|
18 |
1 |
p. 52-62
|
artikel
|
| 48 |
Two-dose schedule for human papillomavirus vaccine
|
Baker, Holly
|
|
2017
|
18 |
1 |
p. e3
|
artikel
|
| 49 |
Unnecessary thyroid cancer screening in South Korea
|
Burki, Talha Khan
|
|
2017
|
18 |
1 |
p. e6
|
artikel
|
| 50 |
US 21st Century Cures Act secures health-care research funding
|
Furlow, Bryant
|
|
2017
|
18 |
1 |
p. 24
|
artikel
|
Tijdschrift beschrijving